Department of Neurosurgery, Kyungpook National University Hospital 50, Samduk-2-ga, Jung-gu, Daegu, 700-721, South Korea.
Acta Neurochir (Wien). 2010 Jul;152(7):1165-70. doi: 10.1007/s00701-010-0610-0. Epub 2010 Mar 5.
We performed a comparative study of the retrogasserian zone (RGZ) with the dorsal root entry zone (DREZ) target to determine effective gamma knife radiosurgery (GKRS) technique in patients with medically refractory trigeminal neuralgia (TN).
We retrospectively reviewed the records of 39 patients with refractory TN undergoing GKRS between April 2005 and October 2008. Until October 2007, DREZ was used as the primary target point. Since November 2007, RGZ has been targeted, located anterior to DREZ. The pain outcome of patient, pain recurrence, and treatment-related complications were evaluated.
Using the Barrow Neurologic Index (BNI) pain score, 15 (93.8%) RGZ and 20 (87.0%) DREZ cases achieved treatment success (BNI pain score I-IIIb) (p = 0.631). Seven (43.8%) RGZ and four (17.4%) DREZ patients reported complete pain relief without medications (BNI pain score I). The time to a response after the GKRS was significantly shorter in the RGZ group (mean 4.1 weeks) than in the DREZ group (mean 6.4 weeks) (p = 0.044). The total complication rate (25.0%) in the RGZ group was similar to the DREZ group (26.1%); however, frequency of bothersome facial numbness and dry eye syndrome was lower in the RGZ group (0%, 0%) compared to the DREZ group (13.1%, 8.7%) (p = 0.255 and 0.503).
The RGZ targeting technique in the GKRS for TN had a better treatment success, with fewer bothersome complications compared to the DREZ target.
我们对经颅神经根入区(DREZ)和后根入区(RGZ)进行了对比研究,以确定伽玛刀放射外科(GKRS)治疗药物难治性三叉神经痛(TN)的有效技术。
我们回顾性分析了 2005 年 4 月至 2008 年 10 月间 39 例药物难治性 TN 患者接受 GKRS 的记录。直到 2007 年 10 月,DREZ 是主要靶点。自 2007 年 11 月以来,RGZ 已成为目标靶点,位于 DREZ 前方。评估了患者的疼痛结果、疼痛复发和治疗相关并发症。
采用巴罗神经病学指数(BNI)疼痛评分,15 例(93.8%)RGZ 和 20 例(87.0%)DREZ 病例达到治疗成功(BNI 疼痛评分 I-IIIb)(p=0.631)。7 例(43.8%)RGZ 和 4 例(17.4%)DREZ 患者报告完全无药物止痛缓解(BNI 疼痛评分 I)。RGZ 组的 GKRS 后反应时间明显短于 DREZ 组(平均 4.1 周)(p=0.044)。RGZ 组的总并发症发生率(25.0%)与 DREZ 组相似(26.1%);然而,RGZ 组面部麻木和干眼症综合征的发生率较低(0%,0%),DREZ 组(13.1%,8.7%)(p=0.255 和 0.503)。
与 DREZ 靶点相比,GKRS 治疗 TN 时,RGZ 靶向技术具有更好的治疗成功率和更少的令人不适的并发症。